Canada Markets closed

Evofem Biosciences, Inc. (EVFM)

OTC Markets OTCQB - OTC Markets OTCQB Delayed Price. Currency in USD
Add to watchlist
0.0115-0.0003 (-2.54%)
At close: 03:07PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0118
Open0.0110
Bid0.0110 x 1100
Ask0.0115 x 1800
Day's Range0.0096 - 0.0115
52 Week Range0.0060 - 0.5490
Volume561,240
Avg. Volume1,371,154
Market Cap713,694
Beta (5Y Monthly)-0.74
PE Ratio (TTM)0.01
EPS (TTM)1.7400
Earnings DateAug 12, 2024 - Aug 16, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st

    Live moderated video webcast with Evofem management on Thursday, August 1 at 10:30am ETSAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women’s health innovator Evofem Biosciences, Inc. (“Evofem” or “the Company”) (OTCQB: EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Chief Business Development Officer, will present and host one-on-one meetings at the OTCQB Venture Virtual Investor Conference as follows: Date:Thursday, August 1, 2024Time:10:30am ETAccess Webca

  • PR Newswire

    Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1

    Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) and private Emirati health care company Pharma 1 Drug Store LLC have signed a License and Supply Agreement for the Middle East rights to Phexxi® (lactic acid, citric acid, potassium bitartrate), Evofem's FDA-approved hormone-free contraceptive.

  • Business Wire

    Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing

    MOUNTAIN VIEW, Calif., July 17, 2024--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.’s ("Evofem") (OTCQB: EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem’s future success, including inter